Given that Alport syndrome is the result of variants in COL4A3, COL4A4 or COL4A5 genes, the ultimate therapy would correct the variant(s) using a gene editing approach, replace the defective network using recombinant collagen α3/α4/α5 protomers, or introduce a correct copy of the defective gene to enough podocytes to be therapeutically beneficial. The gene discussed is COL4A3; the disease is Alport syndrome.